Literature DB >> 7433635

Variegate porphyria. Twelve years' experience in Finland.

P Mustajoki.   

Abstract

Fifty-seven patients with variegate porphyria belonging to nine families are described. The prevalence of variegate porphyria in Finland is 1.3 per 100 000. Eighteen patients had had acute attacks. During on average 5.7 years' follow-up only two of 48 patients had symptoms, which were temporary and acute. The length of life of 13 genealogically traced gene carriers who lived mostly during the 19th century did not differ from that of the general population. Skin fragility occurred in 45 per cent of the patients and was usually mild. No patients were sensitive to sunlight but seven of 14 tested reacted abnormally to artificial light. The characteristic increase in the excretion of faecal proto- and coproporphyrin was usually apparent even in the latent stage of porphyria, but increased excretion of urinary porphyrin precursors occurred only during an acute attack. However, in seven of 48 patients studied during the latent stage, faecal prophyrins were only slightly elevated or even normal, causing problems in diagnosis. Determination of faecal X-porphyrin was of no help in diagnosis. Red cell free protoporphyrin was significantly higher and serum haemopexin lower than in controls. Red cell uroporphyrinogen I synthase activity was normal in 17 of 18 patients studied. We conclude that variegate porphyria may be commoner than hiherto suspected; only half the patients in temperaure and cold climates have skin symptoms, the risk of developing an acute attack is low, and some adult patients excrete normal or only slightly abnormal amounts of porphyrin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7433635

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  10 in total

Review 1.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

2.  The incidence of inherited porphyrias in Europe.

Authors:  George Elder; Pauline Harper; Michael Badminton; Sverre Sandberg; Jean-Charles Deybach
Journal:  J Inherit Metab Dis       Date:  2012-11-01       Impact factor: 4.982

3.  Skin changes in variegate porphyria. Clinical, histopathological, and ultrastructural study.

Authors:  K Timonen; K M Niemi; P Mustajoki; R Tenhunen
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

4.  Porphyrin metabolism and haem biosynthesis in Gilbert's syndrome.

Authors:  K E McColl; G G Thompson; E el Omar; M R Moore; A Goldberg
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

Review 5.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

6.  Functional definition of the tobacco protoporphyrinogen IX oxidase substrate-binding site.

Authors:  Ilka U Heinemann; Nina Diekmann; Ava Masoumi; Michael Koch; Albrecht Messerschmidt; Martina Jahn; Dieter Jahn
Journal:  Biochem J       Date:  2007-03-15       Impact factor: 3.857

7.  Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation.

Authors:  S D Whatley; H Puy; R R Morgan; A M Robreau; A G Roberts; Y Nordmann; G H Elder; J C Deybach
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

8.  Delirium with delayed diagnosis of hereditary coproporphyria.

Authors:  Seyma Eroglu; Ilhan Birsenogul
Journal:  Clin Case Rep       Date:  2022-06-02

9.  Celiac disease or dermatitis herpetiformis in three patients with porphyria.

Authors:  P Mustajoki; M Vuoristo; T Reunala
Journal:  Dig Dis Sci       Date:  1981-07       Impact factor: 3.199

10.  Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium.

Authors:  Herbert L Bonkovsky; Vinaya C Maddukuri; Cemal Yazici; Karl E Anderson; D Montgomery Bissell; Joseph R Bloomer; John D Phillips; Hetanshi Naik; Inga Peter; Gwen Baillargeon; Krista Bossi; Laura Gandolfo; Carrie Light; David Bishop; Robert J Desnick
Journal:  Am J Med       Date:  2014-07-10       Impact factor: 4.965

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.